HCV Clinical Trial
Official title:
Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet
Epclusa® is a pan-genotypic, once-daily tablet for the treatment of chronic hepatitis C virus (HCV) infection containing the NS5B- polymerase inhibitor sofosbuvir (SOF, nucleotide analogue) 400 mg and the NS5A inhibitor velpatasvir (VEL) 100 mg. For patients with swallowing difficulties, administration of whole tablets can be problematic. In addition, HCV patients that are hospitalized (at intensive care units) due to severe illness (co-infections/ liver failure) might not be able to swallow medication. Therefore it is useful to know whether it is possible to administer SOF/VEL through a different route, like a feeding tube. In daily practice, information about the safety and efficacy of crushed tablets is lacking which might result in interruption or discontinuation of expensive HCV therapy. However, it is not recommended to interrupt treatment because there is no evidence about the efficacy of the therapy after discontinuation (and restart). Currently, patients and healthcare professionals are crushing SOF/VEL tablets without information about efficacy and safety. Depending on the biopharmaceutical characteristics of a drug formulation, crushing tablets can lead to altered pharmacokinetics of drugs. It is important to know whether pharmacokinetic parameters are influenced by crushing of tablets; both a decrease and an increase in exposure may occur. A decrease of the plasma concentrations of SOF and/or VEL potentially reduces the therapeutic effect of the drugs. Higher doses or switching to other HCV-drugs might be needed. In contrast, in case a higher Cmax,ss and/or exposure occurs there might be an increased risk of toxicity. As a result, crushing the drug is a contra-indication based on the available data. Therefore this study will be conducted to investigate whether a crushed SOF/VEL tablet is bioequivalent to SOF/VEL as a whole tablet.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05942937 -
National Prisons Hepatitis Education Project: Research Evaluation
|
N/A | |
| Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
| Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
| Recruiting |
NCT05794646 -
Community Intervention to Eliminate HCV Among People Who Use Drugs.
|
N/A | |
| Completed |
NCT04971330 -
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
|
||
| Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
| Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A | |
| Recruiting |
NCT03981445 -
Integrated HIV Prevention and HCV Care for PWID
|
N/A | |
| Completed |
NCT02452814 -
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
|
N/A | |
| Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
| Not yet recruiting |
NCT06316739 -
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
|
N/A | |
| Completed |
NCT02116543 -
TD-6450 MAD Study in HCV Infected Subjects
|
Phase 1 | |
| Recruiting |
NCT05454579 -
The South-East Asian Transgender Health Cohort
|
||
| Active, not recruiting |
NCT03221309 -
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
|
||
| Completed |
NCT03801707 -
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT03820102 -
Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
|
||
| Completed |
NCT01074008 -
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
|
Phase 2 | |
| Completed |
NCT05616598 -
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05854511 -
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
|
Phase 3 | |
| Completed |
NCT03069001 -
Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV
|
Phase 4 |